The available vast body of genetic information may be exploited for treatment of disease either by delivery of proteins or the genetic information itself. Any protein can be expressed in vivo from mRNA. Yet, its production process is independent of the encoded protein. mRNA is thus a powerful therapeutic agent more flexible than protein and it is also decisively safer than competing nucleotide-based approaches. Inevitably, mRNA has emerged as a unique basis for molecular therapy.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Wolff JA, Malone RW, Williams P et al. (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468
Ulmer JB, Mason PW, Geall A et al. (2012) RNA-based vaccines. Vaccine 30:4414–4418
Hoerr I, Obst R, Rammensee HG et al. (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30:1–7
Martinon F, Krishnan S, Lenzen G et al. (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposomeentrapped mRNA. Eur J Immunol 23:1719–1722
Kreiter S, Selmi A, Diken M et al. (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70:9031–9040
Wilgenhof S, Van Nuffel AM, Benteyn D et al. (2013) A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 24:2686–2693
Geall AJ, Verma A, Otten GR (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 109:14604–14609
Fotin-Mleczek M, Duchard KM, Lorenz C et al. (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34:1–15
Petsch B, Schnee M, Vogel AB (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30:1210–1216
Kübler H, Maurer T, Stenzl A et al. (2011) Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. ASCO Annual Meeting, http://meetinglibrary.asco.org/content/83642-102
Karikó K, Muramatsu H, Keller JM et al. (2012) Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther 20:948–953
Warren L, Manos PD, Ahfeldt T (2010) Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:618–630
About this article
Cite this article
Thess, A., Grund, S. Biotechnologie 2.0 — Impfstoffe und Medikamente auf Basis von mRNA. Biospektrum 20, 577–579 (2014). https://doi.org/10.1007/s12268-014-0483-5